[The morphometric characteristics of the erythrocytes and their catecholamine-binding properties in the treatment of stage-II hypertension patients with Renitec].
Morphometric and catecholamine-binding properties of erythrocytes were studied as were their changes in monotherapy with Renitec, an inhibitor of the angiotensin-converting enzyme, of patients with stage II hypertensive disease, using the image digital analysis computing system VIDAS-386 (Kontron Electronik, Germany). Patients with hypertensive disease were shown to develop degenerative changes in their erythrocytes, with catecholamine accumulation in them being a prominent feature, these events taking their course against the background of abnormalities in primary parameters characterizing cardiochemodynamics and regulation of the heart's rhythm. The above patients derived apparent benefit from treatment with Renitec, which fact was evidenced by improvement in parameters associated with the cardiochemodynamics and regulation of the cardiac rhythm, by alleviating the degree of severity of degenerative changes in erythrocytes, and by increase in their content of catecholamines.
Vizir
A D
AD
Ostrovskaia
S V
SV
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002395:Catecholamines / Q000097:blood*; D003936:Diagnosis, Computer-Assisted / Q000295:instrumentation; D004656:Enalapril / Q000627:therapeutic use*; D004912:Erythrocytes / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006651:Histocytochemistry; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002395:Catecholamines; D004656:Enalapril